Comments
The US Food and Drug Administration (USFDA) has cleared Granules India Ltd’s manufacturing facility at Gagillapur here here.
The USFDA has issued an Establishment Inspection Report (EIR) for the facility, the Hyderabad-based company informed the Bombay Stock Exchange on Wednesday.
"The facility was inspected by the USFDA in October 2016 and there were no observations during the inspection,’’ the company said.
The Gagillapur facility manufactures finished dosages and pharmaceutical formulation intermediates.
Granules’ scrip zoomed 8.67 per cent on the BSE on Wednesday to end at Rs 126.44.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.